Towards a constructive dialogue on pharmaceutical pricing

In the recent decade, pharmaceutical companies have experimented with innovative pricing schemes. Despite these efforts, we still find ourselves in a deadlock in the pricing debate.

It is time that pharma and payers start working together to find win-win solutions that balance the needs of pharmaceutical companies, payers and society.

In this paper, we provide a framework to help pharma and payers start a new dialogue and explore where they might find common ground. It provides answers to questions such as: What are the variables to look at and the decisions to make when deciding on a pricing scheme? How do you ensure that a pricing scheme balances the needs of pharmaceutical companies, payers and society?

Read all about it here and we are looking forward to hearing your thoughts on this topic!

Download the white paper

Learn more about compelling pricing, reimbursement and Market Access strategies?

Click here. Do you want more information or want to get started? Please contact Bas Amesz.

Would you like to further discuss this topic?